News | January 09, 2026
Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The approval is backed by data showing deep, durable responses and manageable tolerability
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
GlideTech materials are available in several standard base resins and offer customization options for specific applications
Pravesh brings with him over 29 years of experience in leading complex manufacturing operations and driving operational excellence
Subscribe To Our Newsletter & Stay Updated
